The first safety test is done, and it is good.
Life Biosciences has released the first human Phase 1 clinical trial safety data for ER-100, an AAV2 gene therapy testing partial epigenetic reprogramming in patients with open-angle glaucoma. In this video, we analyze the 56-day safety profile, early visual field perimetry results, and how inducible OSK transcription factors aim to restore optic nerve function.
🧬 SUPPORT THE CHANNEL & LONGEVITY PARTNERS
👉 Seeking Health (10% off: Richard10) https://crrnt.app/SEEK/polxleer — PQQ, https://crrnt.app/SEEK/pPlZ42Wa — CoQ10
Renue By Science (10% off: MHS) https://tinyurl.com/bdew4bfs — NMN Powder • https://tinyurl.com/4eu68vkb — Lipo CoQ10.
Stemregen (15% off: MODERN) US only https://tinyurl.com/45z968yr.
AX3 Life (20% off: MODERN20) https://ax3.life/MODERN20 — Astaxanthin.
n1o1 (10% off: Modern) https://tidd.ly/3IczGRW — Nitric Oxide Lozenges.
Qualia (15% off: MODERN) Creatine+ https://tinyurl.com/mr3z35jd • Senolytic https://bit.ly/4jlaibe.
Wellness Extract (10% off: MODERNWE) http://wellnessextract.com/RICHARDWE — Geranylgeraniol • Vit E
Qitone (10% off: HEALTH10) https://tidd.ly/4jGklry Qitone Esters Powder.
📚 Chapters.
00:00 Cellular Reprogramming & The Glaucoma Challenge.
01:30 Day 56 Safety Results & Dose Escalation.
03:05 Visual Field Improvements: Signal vs Noise.
05:04 How ER-100 Works: Immune Privilege & The OSK Switch.
09:00 Preclinical Science, Epigenetics & What’s Next.
#CellularReprogramming #Longevity #Glaucoma.
For nearly two decades, scientists have explored whether Yamanaka factor cellular reprogramming could safely operate in living humans. Now, Life Biosciences has reported the first-in-human Phase 1 interim safety readout for ER-100, an AAV2-delivered gene therapy targeting retinal ganglion cells in patients with primary open-angle glaucoma.
In this video, we review the 56-day safety data across the initial 3-patient cohort, which demonstrated zero serious adverse events and unanimous Data Safety Monitoring Board approval to advance to a 3-fold higher dose. We break down the early Humphrey visual field perimetry results showing a 4-decibel gain across 28% of test points in 2 patients, while contextualizing the clinical noise and learning effects common in glaucoma testing. Finally, we explore why the eye is the ideal testing ground for gene therapy, how ER-100 uses an oral doxycycline switch to drive OSK without the c-Myc oncogene, and what preclinical work from Dr. David Sinclair’s Harvard lab reveals about reversing vision loss.